Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus

References

• Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:1.
   Web of Science ®Google Scholar
• Pereira PR, Carrageta DF, Oliveira PF, et al. Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease. Med Res Rev. 2022;42(4):1518–9.
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263.
   PubMed Web of Science ®Google Scholar
• Jung CY, Yoo TH. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. Diabetes Metab J. 2022;46(2):181–197.
   PubMed Web of Science ®Google Scholar
• Mitrofanova A, Burke G, Merscher S, et al. New insights into renal lipid dysmetabolism in diabetic kidney disease. World J Diabetes. 2021;12(5):524–540.
   PubMed Web of Science ®Google Scholar
• Grefhorst A, McNutt MC, Lagace TA, et al. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res. 2008;49(6):1303–1311.
   PubMed Web of Science ®Google Scholar
• Schulz R, Schlüter KD, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol. 2015;110(2):4.
   PubMed Web of Science ®Google Scholar
• Shapiro MD, Tavori H, Fazio S. PCSK9: from basic science discoveries to clinical trials. Circ Res. 2018;122(10):1420–1438.
   PubMed Web of Science ®Google Scholar
• Cui Q, Ju X, Yang T, et al. Serum PCSK9 is associated with multiple metabolic factors in a large han chinese population. Atherosclerosis. 2010;213(2):632–636.
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94(7):2537–2543.
   PubMed Web of Science ®Google Scholar
• Yang SH, Li S, Zhang Y, et al. Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes. Diabetes Metab Res Rev. 2016;32(2):193–199.
   PubMed Web of Science ®Google Scholar
• Peng J, Liu MM, Jin JL, et al. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020;19(1):167.
   PubMed Web of Science ®Google Scholar
• Xu M, Wu X, Liu Z, et al. A novel mouse model of diabetes, atherosclerosis and fatty liver disease using an AAV8-PCSK9-D377Y injection and dietary manipulation in db/db mice. Biochem Biophys Res Commun. 2022;622:163–169.
   PubMed Web of Science ®Google Scholar
• Momtazi-Borojeni AA, Jaafari MR, Abdollahi E, et al. Impact of PCSK9 immunization on glycemic indices in diabetic rats. J Diabetes Res. 2021;2021:4757170.
   PubMed Web of Science ®Google Scholar
• Amput P, Palee S, Arunsak B, et al. PCSK9 inhibitor and atorvastatin reduce cardiac impairment in ovariectomized prediabetic rats via improved mitochondrial function and Ca(2+) regulation. J Cell Mol Med. 2020;24(16):9189–9203.
   PubMed Web of Science ®Google Scholar
• Elewa U, Fernández-Fernández B, Mahillo-Fernández I, et al. PCSK9 in diabetic kidney disease. Eur J Clin Invest. 2016;46(9):779–786.
   PubMed Web of Science ®Google Scholar
• Diabetology branch of the Chinese medical association, guidelines for prevention and treatment of type 2 diabetes in China (2020 edition). Chin J Diab. 2021;13:315–409.
   Google Scholar
• Levey AS, Stevens LA, Schmid CH, 3rd, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Bucci T, Ames PR, Cammisotto V, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study. J Autoimmun. 2022;129:102832.
   PubMedGoogle Scholar
• Li A, Yi B, Han H, et al. Vitamin D-VDR (vitamin D receptor) regulates defective autophagy in renal tubular epithelial cell in streptozotocin-induced diabetic mice via the AMPK pathway. Autophagy. 2022;18(4):877–890.
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Petrides F, Tabet F, et al. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. J Clin Lipidol. 2018;12(1):130–136.
   PubMed Web of Science ®Google Scholar
• Nekaies Y, Baudin B, Kelbousi S, et al. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients. J Diab Compli. 2015;29(8):1165–1170.
   PubMed Web of Science ®Google Scholar
• Peng J, Zhu CG, Li JJ. The predictive utility of circulating PCSK9 levels on diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):45.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ye J, Li J, et al. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9). Cardiovasc Diabetol. 2016;15:19.
   PubMed Web of Science ®Google Scholar
• Konarzewski M, Szolkiewicz M, Sucajtys-Szulc E, et al. Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy. Am J Nephrol. 2014;40(2):157–163.
   PubMed Web of Science ®Google Scholar
• Jin K, Park BS, Kim YW, et al. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 2014;63(4):584–589.
   PubMed Web of Science ®Google Scholar
• Haas ME, Levenson AE, Sun X, et al. The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation. 2016;134(1):61–72.
   PubMed Web of Science ®Google Scholar
• Sugahara M, Pak WLW, Tanaka T, et al. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology. 2021;26(6):491–500.
   PubMed Web of Science ®Google Scholar
• Sharotri V, Collier DM, Olson DR, et al. Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J Biol Chem. 2012;287(23):19266–19274.
   PubMed Web of Science ®Google Scholar
• Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010;51(9):2714–2721.
   PubMed Web of Science ®Google Scholar
• Cai G, Yu L, Huang Z, et al. Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population. Lipids Health Dis. 2018;17(1):213.
   PubMed Web of Science ®Google Scholar
• Molina-Jijon E, Gambut S, Macé C, et al. Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome. Kidney Int. 2020;98(6):1449–1460.
   PubMed Web of Science ®Google Scholar
• Kwakernaak AJ, Lambert G, Slagman MC, et al. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment. Atherosclerosis. 2013;226(2):459–465.
   PubMed Web of Science ®Google Scholar